BR112015008042A2 - diagnósticos complementares para terapia com inibidor de quinase da família tec - Google Patents
diagnósticos complementares para terapia com inibidor de quinase da família tecInfo
- Publication number
- BR112015008042A2 BR112015008042A2 BR112015008042A BR112015008042A BR112015008042A2 BR 112015008042 A2 BR112015008042 A2 BR 112015008042A2 BR 112015008042 A BR112015008042 A BR 112015008042A BR 112015008042 A BR112015008042 A BR 112015008042A BR 112015008042 A2 BR112015008042 A2 BR 112015008042A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitor
- tec family
- family kinase
- complementary
- inhibitor therapy
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 7
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000000295 complement effect Effects 0.000 title abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712675P | 2012-10-11 | 2012-10-11 | |
| PCT/US2013/064688 WO2014059368A1 (en) | 2012-10-11 | 2013-10-11 | Companion diagnostics for tec family kinase inhibitor therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008042A2 true BR112015008042A2 (pt) | 2017-07-04 |
Family
ID=49510539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008042A BR112015008042A2 (pt) | 2012-10-11 | 2013-10-11 | diagnósticos complementares para terapia com inibidor de quinase da família tec |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150260723A1 (enExample) |
| EP (1) | EP2906556A1 (enExample) |
| JP (1) | JP2015536446A (enExample) |
| KR (1) | KR20150065871A (enExample) |
| CN (1) | CN104755474A (enExample) |
| AU (1) | AU2013328961A1 (enExample) |
| BR (1) | BR112015008042A2 (enExample) |
| CA (1) | CA2887697A1 (enExample) |
| HK (1) | HK1213892A1 (enExample) |
| MX (1) | MX2015004576A (enExample) |
| WO (1) | WO2014059368A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016010961A1 (en) * | 2014-07-15 | 2016-01-21 | Abbvie Inc. | Enzyme occupancy assay |
| AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
| CA2967853A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Patent Gmbh | Assays for btk inhibitors |
| WO2016100593A1 (en) * | 2014-12-17 | 2016-06-23 | Pharmacyclics Llc | Methods and assays for quantification and normalization of kinase and ligand binding |
| GB201502393D0 (en) * | 2015-02-13 | 2015-04-01 | Univ Leicester | Senescence |
| US20200166507A1 (en) * | 2016-02-15 | 2020-05-28 | Nobelpharma Co., Ltd. | Measurement method and measurement kit for proteins related to genetic diseases |
| CN109715166A (zh) | 2016-07-14 | 2019-05-03 | 深圳明赛瑞霖药业有限公司 | 癌症的治疗 |
| CN106405086A (zh) * | 2016-09-21 | 2017-02-15 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| WO2018134786A1 (en) * | 2017-01-19 | 2018-07-26 | Acerta Pharma B.V. | Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase |
| EP3514541A1 (de) * | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors |
| JP2024520630A (ja) | 2021-06-04 | 2024-05-24 | ヤンセン ファーマシューティカ エヌ．ベー． | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 |
| CN114200145A (zh) * | 2022-02-18 | 2022-03-18 | 上海益诺思生物技术股份有限公司 | 酪氨酸激酶浓度的检测方法及试剂盒 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
-
2013
- 2013-10-11 JP JP2015536969A patent/JP2015536446A/ja active Pending
- 2013-10-11 HK HK16101892.9A patent/HK1213892A1/zh unknown
- 2013-10-11 CA CA2887697A patent/CA2887697A1/en not_active Abandoned
- 2013-10-11 BR BR112015008042A patent/BR112015008042A2/pt not_active IP Right Cessation
- 2013-10-11 KR KR1020157011983A patent/KR20150065871A/ko not_active Withdrawn
- 2013-10-11 EP EP13783762.1A patent/EP2906556A1/en not_active Withdrawn
- 2013-10-11 CN CN201380052463.6A patent/CN104755474A/zh active Pending
- 2013-10-11 WO PCT/US2013/064688 patent/WO2014059368A1/en not_active Ceased
- 2013-10-11 US US14/434,015 patent/US20150260723A1/en not_active Abandoned
- 2013-10-11 AU AU2013328961A patent/AU2013328961A1/en not_active Abandoned
- 2013-10-11 MX MX2015004576A patent/MX2015004576A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2906556A1 (en) | 2015-08-19 |
| AU2013328961A1 (en) | 2015-05-07 |
| KR20150065871A (ko) | 2015-06-15 |
| MX2015004576A (es) | 2015-07-21 |
| JP2015536446A (ja) | 2015-12-21 |
| CN104755474A (zh) | 2015-07-01 |
| US20150260723A1 (en) | 2015-09-17 |
| WO2014059368A1 (en) | 2014-04-17 |
| CA2887697A1 (en) | 2014-04-17 |
| HK1213892A1 (zh) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
| Agner et al. | Classification of hand eczema | |
| Padmos et al. | A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112019004075A2 (pt) | métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit. | |
| BR112014007214A2 (pt) | predição de evento de risco cardiovascular e utilização do mesmo | |
| Lagerstedt et al. | H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| BR112014016719A2 (pt) | sistema e método para gestão de plano de cuidados de pacientes | |
| BR112018015698A2 (pt) | ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos? | |
| EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
| BR112017008218A2 (pt) | métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal | |
| IN2014DN08537A (enExample) | ||
| Williams et al. | Perioperative anxiety and depression in patients undergoing abdominal surgery for benign or malignant disease | |
| BR112016023170A2 (pt) | biomarcadores para avaliação de hiv | |
| PE20180930A1 (es) | Composiciones y metodos para la vigilancia activa del cancer de prostata | |
| BR112015014232A2 (pt) | lesão renal aguda | |
| Schlaeger et al. | Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? | |
| BR112015021507A8 (pt) | métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico | |
| Silsby et al. | The midbrain‐to‐pons ratio distinguishes progressive supranuclear palsy from non‐fluent primary progressive aphasias | |
| Saunders et al. | Evolution and future directions for the concept of mild cognitive impairment | |
| Bahat et al. | Associations between obesity, self-reported weakness and their combinations with mortality in nursing home residents | |
| BR112018070970A2 (pt) | método para diagnóstico de fibrose cística | |
| Forti et al. | The physical phenotype of frailty for risk stratification of older medical inpatients | |
| Mishra et al. | Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |